Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

2 days ago
R&D

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

2 days ago
Pharma
Regulatory

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

2 days ago
Pharma

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

2 days ago
Pharma

The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

2 days ago
R&D

Bain's Or­ly Mis­han joins Pfiz­er's neu­ro spin­out Cerev­el; On­colyt­ic virus biotech taps Sil­la­Jen ex­ec He­le­na Chaye as CEO

2 days ago
Peer Review

A bud­get biotech you like­ly nev­er heard about is set­ting a course for Wall Street with some mod­est am­bi­tions

2 days ago
IPOs

UP­DAT­ED: Watch out Bay­er, Roche is com­ing for you with a dis­count price ri­val to the tu­mor ag­nos­tic drug you got from Loxo

3 days ago
R&D

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

3 days ago
People
Pharma

Soar­ing De­ci­phera cap­i­tal­izes on pos­i­tive tri­al with $400M of­fer­ing; Spring­Work hires ex-For­est Labs CFO

3 days ago
Protocols

Re­gen­eron puts fin­ish­ing touch­es on $800M ex­pan­sion project close to home

3 days ago
R&D

A PARP suc­ces­sor? Michi­gan aca­d­e­m­ic team touts po­ten­tial of an ag­ing — but still ex­per­i­men­tal — As­traZeneca drug in DNA dam­age re­pair

3 days ago
R&D

UP­DAT­ED: Ail­ing Mallinck­rodt's drug for rare, life-threat­en­ing re­nal con­di­tion clears piv­otal study

3 days ago
Pharma
R&D

New re­search ques­tions FDA’s re­liance on and in­abil­i­ty to en­force post­mar­ket­ing re­quire­ments

3 days ago
Regulatory

One of the 'mir­a­cle cures' to hit the streets is re­al­ly just in­dus­tri­al bleach — and it can kill you

3 days ago
Regulatory

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

3 days ago
Biotech Voices
China

On the cusp of PhI, An­gel­man-fo­cused biotech scores po­ten­tial buy­out deal from Ul­tragenyx

3 days ago
Deals

FDA en­dors­es new reg­i­men for dead­ly drug-re­sis­tant tu­ber­cu­lo­sis ram­pant in de­vel­op­ing world

3 days ago
Pharma
R&D

The re­al-world ev­i­dence project at the FDA adds Syapse to its list of part­ners in a push past tri­al bound­aries

3 days ago
R&D
Regulatory

Macro­Gen­ics vs Mer­ck: An un­der­dog plans a pre­mier bout with the heavy­weight cham­pi­on of the PD-1 class

3 days ago
R&D

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

4 days ago
People

Sen­a­tors ac­cuse Te­va, My­lan of stonewalling price fix­ing probe; Myr­i­ad Ge­net­ics shares skid on dis­mal quar­ter­ly re­sults

4 days ago
Protocols

Armed with stel­lar — if niche — PhI­II da­ta, Re­gen­eron steers 'break­through' cho­les­terol drug to post-PC­SK9 wa­ters

4 days ago
R&D

Johns Hop­kins sci­en­tists raise $137M megaround for a trio of spin­outs look­ing to tack­le Alzheimer’s, Parkin­son’s and fi­bro­sis

4 days ago
Startups
Venture
1234 Next page Last page